IL155810A0 - Nmda receptor agonist pharmaceutical compositions - Google Patents

Nmda receptor agonist pharmaceutical compositions

Info

Publication number: IL155810A0
Authority: IL; Israel
Prior art keywords: pharmaceutical compositions; receptor agonist; nmda receptor; agonist pharmaceutical; nmda
Prior art date: 2000-12-13

Application number

IL15581001A

Other languages

English (en)

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-13

Filing date

2001-12-05

Publication date

2003-12-23

2001-12-05 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2003-12-23 Publication of IL155810A0 publication Critical patent/IL155810A0/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Inorganic Chemistry (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Addiction (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

IL15581001A 2000-12-13 2001-12-05 Nmda receptor agonist pharmaceutical compositions IL155810A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US25537200P	2000-12-13	2000-12-13
PCT/IB2001/002359 WO2002047685A2 (en)	2000-12-13	2001-12-05	Nmda receptor agonist pharmaceutical compositions

Publications (1)

Publication Number	Publication Date
IL155810A0 true IL155810A0 (en)	2003-12-23

Family

ID=22968017

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL15581001A IL155810A0 (en)	2000-12-13	2001-12-05	Nmda receptor agonist pharmaceutical compositions

Country Status (41)

Country	Link
US (2)	US6635270B2 (et)
EP (1)	EP1347760B1 (et)
JP (1)	JP2004515529A (et)
KR (1)	KR100533407B1 (et)
CN (1)	CN1273135C (et)
AP (1)	AP1235A (et)
AR (1)	AR035607A1 (et)
AT (1)	ATE296629T1 (et)
AU (2)	AU2002218454B2 (et)
BG (1)	BG107788A (et)
BR (1)	BR0116085A (et)
CA (1)	CA2431172A1 (et)
CZ (1)	CZ20031543A3 (et)
DE (1)	DE60111265T2 (et)
DO (1)	DOP2001000300A (et)
DZ (1)	DZ3484A1 (et)
EA (1)	EA006489B1 (et)
EC (1)	ECSP034655A (et)
EE (1)	EE200300284A (et)
ES (1)	ES2239648T3 (et)
GE (1)	GEP20053568B (et)
HR (1)	HRP20030473A2 (et)
HU (1)	HUP0400645A2 (et)
IL (1)	IL155810A0 (et)
IS (1)	IS6811A (et)
MA (1)	MA26970A1 (et)
MX (1)	MXPA03005257A (et)
NO (1)	NO20032678L (et)
NZ (1)	NZ525742A (et)
OA (1)	OA12414A (et)
PA (1)	PA8534901A1 (et)
PE (1)	PE20020710A1 (et)
PL (1)	PL362080A1 (et)
PT (1)	PT1347760E (et)
SK (1)	SK6982003A3 (et)
TN (1)	TNSN01173A1 (et)
UA (1)	UA73619C2 (et)
UY (1)	UY27068A1 (et)
WO (1)	WO2002047685A2 (et)
YU (1)	YU41103A (et)
ZA (1)	ZA200303892B (et)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN104383542B (zh)	2003-04-08	2017-09-26	普罗热尼奇制药公司	包含甲基纳曲酮的药物配方
TW200800959A (en) *	2005-06-10	2008-01-01	Wyeth Corp	Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
TW200808741A (en) *	2006-06-09	2008-02-16	Wyeth Corp	6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
TW200808740A (en) *	2006-06-09	2008-02-16	Wyeth Corp	Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
TW200811144A (en) *	2006-06-09	2008-03-01	Wyeth Corp	Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
TWI489984B (zh)	2006-08-04	2015-07-01	Wyeth Corp	用於非經腸道傳輸化合物之配方及其用途
AR063984A1 (es) *	2006-11-28	2009-03-04	Wyeth Corp	Metabolitos de 5-fluoro-8-{4-[4-(6-metoxiquinolin-8-il)piperazin-1-il]piperidin-1-il}quinolina, metodos de preparacion, su uso en la fabricacion de medicamentos para el tratamiento de trastornos relacionados con 5-ht1a, composicion farmaceutica que los comprende, compuestos radioetiquetados derivado
CL2008000119A1 (es)	2007-01-16	2008-05-16	Wyeth Corp	Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia.
CN101317844B (zh) *	2007-06-08	2010-11-17	章劲夫	化合物(+)-5-甲基-10，11-二氢-5H-二苯并〔a，d〕环庚烯-5，10-亚胺在制备避孕药物中的应用
CA2740628C (en)	2008-09-18	2018-05-01	Naurex, Inc.	Nmda receptor modulators and uses thereof
US8951968B2 (en)	2009-10-05	2015-02-10	Northwestern University	Methods of treating depression and other related diseases
ES2706063T3 (es)	2010-02-11	2019-03-27	Univ Northwestern	Agonistas del receptor de NMDA y usos del mismo
KR101692275B1 (ko)	2010-02-11	2017-01-04	노오쓰웨스턴 유니버시티	２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
CN102586243A (zh) *	2012-03-08	2012-07-18	中国人民解放军军事医学科学院放射与辐射医学研究所	一种预防电磁辐射致脑损伤的标志物
US20140206667A1 (en)	2012-11-14	2014-07-24	Michela Gallagher	Methods and compositions for treating schizophrenia
HRP20190613T1 (hr)	2013-01-29	2019-06-28	Aptinyx Inc.	Spiro-laktam modulatori nmda receptora i njihove uporabe
BR112015018089B1 (pt)	2013-01-29	2022-09-20	Aptinyx Inc	Compostos moduladores de receptor de nmda de espiro-lactama, composição farmacêutica os compreendendo e uso dos mesmos
EP2951185B1 (en)	2013-01-29	2016-12-21	Aptinyx Inc.	Spiro-lactam nmda receptor modulators and uses thereof
KR20150110787A (ko)	2013-01-29	2015-10-02	노렉스, 인크.	스피로-락탐 nmda 수용체 조절인자 및 그의 용도
US9738650B2 (en)	2013-01-29	2017-08-22	Aptinyx Inc.	Spiro-lactam NMDA receptor modulators and uses thereof
WO2015099381A1 (ko)	2013-12-23	2015-07-02	주식회사 삼양바이오팜	팔로노세트론을 함유하는 약학 조성물
CN109415372B (zh)	2016-05-19	2021-01-15	阿普廷伊克斯股份有限公司	螺-内酰胺nmda受体调节剂及其用途
WO2017201285A1 (en)	2016-05-19	2017-11-23	Aptinyx Inc.	Spiro-lactam nmda receptor modulators and uses thereof
PE20190503A1 (es)	2016-08-01	2019-04-10	Aptinyx Inc	Moduladores del receptor nmda espiro-lactam y uso de los mismos
BR112019001921A2 (pt)	2016-08-01	2019-05-14	Aptinyx Inc.	moduladores do receptor nmda de espiro-lactama e seus usos
EP3490994B8 (en)	2016-08-01	2024-03-13	Tenacia Biotechnology (Hong Kong) Co., Limited	Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
MX388786B (es)	2016-08-01	2025-03-20	Aptinyx Inc	Moduladores nmda espiro-lactam y métodos de uso de los mismos.
IL286107B2 (en)	2016-08-01	2024-09-01	Aptinyx Inc	Spiro-lactam nmda receptor modulators and usesthereof
WO2019152687A1 (en)	2018-01-31	2019-08-08	Aptinyx Inc.	Spiro-lactam nmda receptor modulators and uses thereof
US12012413B2 (en)	2019-11-11	2024-06-18	Tenacia Biotechnology (Hong Kong) Co., Limited	Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5272160A (en) *	1989-05-17	1993-12-21	Pfizer Inc	2-piperidino-1-alkanol derivatives as antiischemic agents
US5710168A (en) *	1991-10-23	1998-01-20	Pfizer Inc.	2-piperidino-1-alkanol derivatives as neuroprotective agents
TR199800208T1 (et) *	1995-08-11	1998-05-21	Pfizer Inc.
TW450807B (en) *	1995-09-15	2001-08-21	Pfizer	Pharmaceutical compositions for treating tinnitus comprising neuroprotective agents

2001
- 2001-05-12 UA UA2003065485A patent/UA73619C2/uk unknown
- 2001-12-05 IL IL15581001A patent/IL155810A0/xx unknown
- 2001-12-05 SK SK698-2003A patent/SK6982003A3/sk unknown
- 2001-12-05 DZ DZ013484A patent/DZ3484A1/fr active
- 2001-12-05 AU AU2002218454A patent/AU2002218454B2/en not_active Ceased
- 2001-12-05 PL PL01362080A patent/PL362080A1/xx not_active Application Discontinuation
- 2001-12-05 KR KR10-2003-7007874A patent/KR100533407B1/ko not_active Expired - Fee Related
- 2001-12-05 PT PT01270205T patent/PT1347760E/pt unknown
- 2001-12-05 NZ NZ525742A patent/NZ525742A/en unknown
- 2001-12-05 AU AU1845402A patent/AU1845402A/xx active Pending
- 2001-12-05 HR HR20030473A patent/HRP20030473A2/hr not_active Application Discontinuation
- 2001-12-05 EP EP01270205A patent/EP1347760B1/en not_active Expired - Lifetime
- 2001-12-05 OA OA1200300145A patent/OA12414A/en unknown
- 2001-12-05 CN CNB018203922A patent/CN1273135C/zh not_active Expired - Fee Related
- 2001-12-05 GE GE5171A patent/GEP20053568B/en unknown
- 2001-12-05 JP JP2002549256A patent/JP2004515529A/ja active Pending
- 2001-12-05 EA EA200300514A patent/EA006489B1/ru not_active IP Right Cessation
- 2001-12-05 CA CA002431172A patent/CA2431172A1/en not_active Abandoned
- 2001-12-05 AT AT01270205T patent/ATE296629T1/de not_active IP Right Cessation
- 2001-12-05 EE EEP200300284A patent/EE200300284A/et unknown
- 2001-12-05 US US10/010,827 patent/US6635270B2/en not_active Expired - Fee Related
- 2001-12-05 HU HU0400645A patent/HUP0400645A2/hu unknown
- 2001-12-05 ES ES01270205T patent/ES2239648T3/es not_active Expired - Lifetime
- 2001-12-05 BR BR0116085-0A patent/BR0116085A/pt not_active IP Right Cessation
- 2001-12-05 MX MXPA03005257A patent/MXPA03005257A/es active IP Right Grant
- 2001-12-05 WO PCT/IB2001/002359 patent/WO2002047685A2/en not_active Ceased
- 2001-12-05 CZ CZ20031543A patent/CZ20031543A3/cs unknown
- 2001-12-05 DE DE60111265T patent/DE60111265T2/de not_active Expired - Fee Related
- 2001-12-05 YU YU41103A patent/YU41103A/sh unknown
- 2001-12-10 DO DO2001000300A patent/DOP2001000300A/es unknown
- 2001-12-11 PE PE2001001235A patent/PE20020710A1/es not_active Application Discontinuation
- 2001-12-11 AR ARP010105748A patent/AR035607A1/es unknown
- 2001-12-12 UY UY27068A patent/UY27068A1/es not_active Application Discontinuation
- 2001-12-12 TN TNTNSN01173A patent/TNSN01173A1/fr unknown
- 2001-12-13 PA PA20018534901A patent/PA8534901A1/es unknown
- 2001-12-13 AP APAP/P/2001/002376A patent/AP1235A/en active
2003
- 2003-05-08 IS IS6811A patent/IS6811A/is unknown
- 2003-05-09 BG BG107788A patent/BG107788A/bg unknown
- 2003-05-20 ZA ZA200303892A patent/ZA200303892B/en unknown
- 2003-06-03 MA MA27191A patent/MA26970A1/fr unknown
- 2003-06-12 NO NO20032678A patent/NO20032678L/no not_active Application Discontinuation
- 2003-06-13 EC EC2003004655A patent/ECSP034655A/es unknown
- 2003-08-19 US US10/643,441 patent/US20040039022A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DE60111265T2 (de)	2006-05-04
ECSP034655A (es)	2003-07-25
CN1479617A (zh)	2004-03-03
ZA200303892B (en)	2004-05-20
EP1347760A2 (en)	2003-10-01
ES2239648T3 (es)	2005-10-01
DE60111265D1 (de)	2005-07-07
US20020111366A1 (en)	2002-08-15
NO20032678D0 (no)	2003-06-12
TNSN01173A1 (fr)	2005-11-10
CZ20031543A3 (cs)	2004-06-16
YU41103A (sh)	2006-05-25
AP2001002376A0 (en)	2001-12-31
KR20030070060A (ko)	2003-08-27
AR035607A1 (es)	2004-06-16
AU1845402A (en)	2002-06-24
GEP20053568B (en)	2005-07-11
NZ525742A (en)	2005-07-29
MA26970A1 (fr)	2004-12-20
OA12414A (en)	2006-04-18
BG107788A (bg)	2004-01-30
DZ3484A1 (fr)	2002-06-20
EA006489B1 (ru)	2005-12-29
MXPA03005257A (es)	2003-09-25
HRP20030473A2 (en)	2005-04-30
HUP0400645A2 (hu)	2004-06-28
WO2002047685A3 (en)	2002-08-15
EE200300284A (et)	2003-10-15
WO2002047685A2 (en)	2002-06-20
CN1273135C (zh)	2006-09-06
JP2004515529A (ja)	2004-05-27
EA200300514A1 (ru)	2003-10-30
BR0116085A (pt)	2003-12-23
AU2002218454B2 (en)	2005-10-27
KR100533407B1 (ko)	2005-12-02
UY27068A1 (es)	2002-07-31
DOP2001000300A (es)	2002-05-30
PA8534901A1 (es)	2002-08-26
PL362080A1 (en)	2004-10-18
ATE296629T1 (de)	2005-06-15
HK1059575A1 (en)	2004-07-09
NO20032678L (no)	2003-06-12
PT1347760E (pt)	2005-09-30
UA73619C2 (en)	2005-08-15
PE20020710A1 (es)	2002-08-09
EP1347760B1 (en)	2005-06-01
US20040039022A1 (en)	2004-02-26
CA2431172A1 (en)	2002-06-20
SK6982003A3 (en)	2004-08-03
US6635270B2 (en)	2003-10-21
AP1235A (en)	2004-01-06
IS6811A (is)	2003-05-08

Publication	Publication Date	Title
IL155810A0 (en)	2003-12-23	Nmda receptor agonist pharmaceutical compositions
PL365377A1 (en)	2005-01-10	Amide derivatives as nmda receptor antagonists
HUP0203870A3 (en)	2005-07-28	Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
SI2277521T1 (sl)	2015-07-31	Oralne formulacije opioidnih agonistov, varne pred zlorabo
EG24194A (en)	2008-10-14	5ht-a-partial agonist pharmaceutical compositions
AU2001296013A1 (en)	2002-05-15	Pgd2 receptor antagonistic pharmaceutical compositions
IL161997A (en)	2005-12-18	Pharmaceutical composition comprising a 5ht1 receptor agonist
AU8576801A (en)	2002-01-02	Pharmaceutical compositions
HUP0300419A3 (en)	2005-07-28	Estrogen agonist/antagonist metabolites, pharmaceutical compositions containing them and their use
EP1296958A4 (en)	2004-01-28	ANTIAGONISTS OF NMDA NR2B RECEPTORS OF IMINOPYRIMIDINE
IL160715A0 (en)	2004-08-31	Pharmaceutical compositions containing an a1 adenosine receptor antagonist
AU1390002A (en)	2002-03-22	Pharmaceutical compositions
AU2001286409A1 (en)	2002-02-18	N-methyl-d-aspartate receptor antagonists
HUP0200057A3 (en)	2004-03-29	Dopamine d1 receptor agonist compounds, pharmaceutical compositions containing them and their use
SI1347760T1 (en)	2005-10-31	Nmda receptor agonist pharmaceutical compositions
GB0015901D0 (en)	2000-08-23	Compositions containing 5ht receptor agonists
GB0107914D0 (en)	2001-05-23	7tm receptor hlwar77
IL131864A0 (en)	2001-03-19	Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist